The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.
We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.
Conclusion This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single agent blinatumomab.
Li, Z., & Liu, D. (2016). Cell therapy must be regulated as medicine. Experimental Hematology & Oncology, 5, 26. doi:10.1186/s40164-016-0055-0